Telmisartan works by selectively blocking the binding of angiotensin II to AT1 receptors, thereby reducing angiotensin II-induced peripheral vessel constriction, aldosterone-secretion, and sodium reabsorption.
Hypotension, Orthostatic hypotension, Hyperkalaemia, Bradycardia, Chest pain, Tachycardia, Palpitation, Difficulty in breathing, Hypertension, Peripheral oedema, Intermittent claudication, Increased serum creatinine, Tinnitus, Vertigo.
Avoid drinking alcohol. It can further lower your blood pressure and may exaggerate some of the side effects of telmisartan.
The use of telmisartan is not recommended in the first trimester and it is not allowed during the second and third trimester. It is proved that telmisartan will exert toxic effects on the human foetus during the second and third trimester.
There is no information available regarding the use of telmisartan during breast-feeding, therefore, it is not recommended. Alternative treatments with better-established safety profiles during breast-feeding are preferable.
Do not drive unless you are feeling well. Telmisartan may cause side effects such as dizziness or drowsiness, all of which could affect the ability to concentrate and drive.
Telmisartan effectively and safely reduces blood pressure and brought about the regression of proteinuria in diabetic and non-diabetic, hypertensive, proteinuric patients with chronic kidney disease, even in those with mild-to-moderate chronic renal failure.
Occasional elevations of liver chemistries occurred in patients treated with telmisartan. Dose adjustment may be required in patients with mild to moderate liver impairment. It is contraindicated in patients with severe liver impairment.